IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Extrapulmonary Interventional Ventilatory Support in Severe Acute Respiratory Distress Syndrome (ARDS) (Xtravent)
This study has been completed.
Sponsor:
University of Regensburg
Collaborator:
Charite University, Berlin, Germany
Information provided by:
University of Regensburg
ClinicalTrials.gov Identifier:
NCT00538928
First received: October 2, 2007
Last updated: March 1, 2011
Last verified: March 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A prospective, randomized study will be performed investigating the effects of a pumpless extracorporeal interventional lung assist [iLA] on the implementation of a lung-protective ventilatory strategy in patients with acute respiratory distress syndrome [ARDS] with a PaO2/FiO2 ratio < 200. The duration of ventilation, intensive care and hospital stay and in-hospital mortality will be investigated.
| Condition | Intervention |
|---|---|
| Acute Respiratory Distress Syndrome | Other: lung protective ventilation |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Extrapulmonary Interventional Ventilatory Support for Lung Protection in Severe Acute Respiratory Distress - a Prospective Randomized Multi Centre Study |
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources:
Respiratory Distress Syndrome, Infant
Acute Respiratory Distress Syndrome
U.S. FDA Resources
Further study details as provided by University of Regensburg:
Primary Outcome Measures:
- Ventilator free days within 28 days after enrollment [ Time Frame: 28 days ]
Secondary Outcome Measures:
- hospital mortality, organ-failure free days, pulmonary gas exchange [ Time Frame: 28 days - 60 days ]
| Estimated Enrollment: | 120 |
| Study Start Date: | September 2007 |
| Study Completion Date: | January 2011 |
| Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Intervention: Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.
|
Other: lung protective ventilation
tidal volume 6 ml/kg ideal body weight
|
|
Active Comparator: 2
no device: Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).
|
Other: lung protective ventilation
tidal volume 6 ml/kg ideal body weight
|
Detailed Description:
Evaluation group:
Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.
Control group:
Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- The trial subjects are patients aged 18 years or older who have developed severe ARDS. Following the American-European Consensus Conference on ARDS, severe ARDS is defined as an oxygenation index (PaO2/FIO2) < 200 mmHg. These parameters must be present for a duration of at least 2 hours.
Exclusion Criteria:
- age < 18 years
- decompensated heart insufficiency
- acute coronary syndrome
- severe chronic obstructive pulmonary disease
- advanced tumour conditions with life expectancy < 6 months
- chronic dialysis treatment
- lung transplant patients
- proven Heparin-induced thrombocytopenia (HIT)
- morbid obesity (BMI >) 40
- Child Class B and C cirrhosis of the liver, acute fulminant hepatic failure
- severe peripheral arterial occlusive disease (pAVK III - IV), absence of limb doppler pulse
- brain injury (GCS < 9 + CT pathology)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00538928
Please refer to this study by its ClinicalTrials.gov identifier: NCT00538928
Locations
| Germany | |
| University Hospital Regensburg | |
| Regensburg, Germany, 93042 | |
Sponsors and Collaborators
University of Regensburg
Charite University, Berlin, Germany
Investigators
| Principal Investigator: | Thomas Bein, Professor Dr. | University Hospital Regensburg |
| Study Chair: | Steffen Weber-Carstens, Dr. | Charite University Hospital Berlin |
| Study Chair: | Thomas Staudinger, Prof | University Hospital Vienna, Austria |
| Study Chair: | Sven Bercker, MD | University Hospital Leipzig, Germany |
| Study Chair: | Ralph Müllenbach, MD PhD | University Hospital Würzburg, Germany |
| Study Chair: | Rolf Dembinski, MD PhD | University Hospital Aachen, Germany |
More Information
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Department of Anesthesia, University Hospital |
| ClinicalTrials.gov Identifier: | NCT00538928 History of Changes |
| Other Study ID Numbers: |
KKS 4012-001-07 |
| Study First Received: | October 2, 2007 |
| Last Updated: | March 1, 2011 |
Keywords provided by University of Regensburg:
|
acute respiratory distress syndrome extracorporeal lung support hypoxia hypercapnia acute respiratory distress syndrome (ARDS) |
Additional relevant MeSH terms:
|
Syndrome Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Disease Pathologic Processes |
Lung Diseases Respiratory Tract Diseases Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases Lung Injury |
ClinicalTrials.gov processed this record on July 27, 2017